NAVIGATE-2NCT07225959
A Study of Annual Doses of MK-1406/CD388 in Healthy Adults (MK-1406-006/CD388.SQ.2.07)
StatusActive, Not Recruiting
PhasePhase 2
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 4 words
- Trial sites reduced: 6 → 3 locations
- Secondary endpoints: details revised at 4 of 6 entries
Notable Primary endpoint(s) modifiedv4 Show 7 more changesShow less
- Eligibility criteria shortened, about 981 words
- Trial sites expanded: 3 → 6 locations
- Primary and study completion dates: Jul 2027 to Jul 31, 2027
- Interventions: CD388 Injection (Combination Product) to MK-1406 Injection (Combination Product)
- Secondary endpoints revised (6)
- Study title shortened, about 6 words
- Study description expanded, about 1 word
- Notable Changed Sponsor changed: Cidara Therapeutics Inc. to Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Minor Trial status: Recruiting to Active, Not Recruiting
- Site details revised at 3 of 3 sites
- Minor Site details revised at 1 of 3 sitesv2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Number of Participants with Treatment-Induced Anti-Drug Antibodies (ADAs)
Timeframe: Periods 1 and 2: Day 1, Day 29, Day 85, Day 169, and Day 197
Number of Participants with Treatment-Boosted ADAs
Timeframe: Periods 1 and 2: Day 1, Day 29, Day 85, Day 169, and Day 197
Secondary (6)
Number of participants with ≥1 Adverse Event (AE)
Number of Participants Who Discontinued from the Study Due to an AE
Number of Participants with a Solicited Injection-site AE
Number of Participants with a Serious Adverse Event (SAE)
Plasma Concentration Following Administration of MK-1406
Show 1 moreShow less
Plasma concentration of MK-1406 by anti-drug antibody (ADA) status.
Arms and interventions
MK-1406Experimental
Participant will receive 450 mg dose of MK-1406 (CD388) by subcutaneous (SC) injection followed 1 year later by a repeat single 450 mg dose of MK-1406 administered by SC injection.
Combination products: MK-1406 Injection
Sites
3 sites in 2 countries
United States 2, United Kingdom 1